Somaxon Backs Silenor Sales Efforts with $45M Financing
By Trista Morrison
Thursday, August 4, 2011
Somaxon Pharmaceuticals Inc. continued to slog through the crowded insomnia market with Silenor (doxepin) during the second quarter, growing net sales to $6.2 million a 170 percent increase over the $2.3 million sold last quarter, and ahead of the $4 million analysts had expected.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.